139 related articles for article (PubMed ID: 12458677)
1. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.
Rouquayrol M; Gaucher B; Roche D; Greiner J; Vierling P
Pharm Res; 2002 Nov; 19(11):1704-12. PubMed ID: 12458677
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.
Rouquayrol M; Gaucher B; Greiner J; Aubertin AM; Vierling P; Guedj R
Carbohydr Res; 2001 Nov; 336(3):161-80. PubMed ID: 11705466
[TBL] [Abstract][Full Text] [Related]
3. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P
Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863
[TBL] [Abstract][Full Text] [Related]
4. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport.
Roche D; Greiner J; Aubertin AM; Vierling P
Bioconjug Chem; 2006; 17(6):1568-81. PubMed ID: 17105238
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
Roche D; Greiner J; Aubertin AM; Vierling P
Eur J Med Chem; 2008 Jul; 43(7):1506-18. PubMed ID: 17950955
[TBL] [Abstract][Full Text] [Related]
8. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
9. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux.
Jain R; Agarwal S; Mandava NK; Sheng Y; Mitra AK
Int J Pharm; 2008 Oct; 362(1-2):44-51. PubMed ID: 18620036
[TBL] [Abstract][Full Text] [Related]
10. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
11. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Ronaldson PT; Lee G; Dallas S; Bendayan R
Pharm Res; 2004 May; 21(5):811-8. PubMed ID: 15180339
[TBL] [Abstract][Full Text] [Related]
12. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Kim RB; Fromm MF; Wandel C; Leake B; Wood AJ; Roden DM; Wilkinson GR
J Clin Invest; 1998 Jan; 101(2):289-94. PubMed ID: 9435299
[TBL] [Abstract][Full Text] [Related]
13. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6.
Bode H; Schmidt W; Schulzke JD; Fromm M; Zippel T; Wahnschaffe U; Bendfeldt K; Riecken EO; Ullrich R
AIDS; 1999 Dec; 13(18):2595-7. PubMed ID: 10630532
[No Abstract] [Full Text] [Related]
14. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
15. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Gao W; Kageyama M; Inoue Y; Tadano J; Fukumoto K; Fukushima K; Yamasaki D; Nishimura A; Yoshikawa Y; Shibata N; Takada K
Biol Pharm Bull; 2003 Feb; 26(2):199-204. PubMed ID: 12576680
[TBL] [Abstract][Full Text] [Related]
16. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.
Jain R; Duvvuri S; Kansara V; Mandava NK; Mitra AK
Int J Pharm; 2007 May; 336(2):233-40. PubMed ID: 17207946
[TBL] [Abstract][Full Text] [Related]
17. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir.
Wang Z; Pal D; Mitra AK
J Pharm Sci; 2012 Sep; 101(9):3199-213. PubMed ID: 22611042
[TBL] [Abstract][Full Text] [Related]
19. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Aungst BJ; Nguyen NH; Bulgarelli JP; Oates-Lenz K
Pharm Res; 2000 Oct; 17(10):1175-80. PubMed ID: 11145221
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir.
Farèse-Di Giorgio A; Rouquayrol M; Greiner J; Aubertin AM; Vierling P; Guedj R
Antivir Chem Chemother; 2000 Mar; 11(2):97-110. PubMed ID: 10819434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
